The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales

Eoghan M. McCarthy¹, Emily Sutton², Stephanie Nesbit ², James White², Ben Parker¹,³, David Jayne⁴, Bridget Griffiths⁵, David A. Isenberg⁶, Anisur Rahman⁶, Caroline Gordon⁷,⁸, David P. D'Cruz⁹, Benjamin Rhodes¹⁰, Peter Lanyon¹¹, Edward M. Vital¹²,¹³, Chee-Seng Yee¹⁴, Christopher J. Edwards¹⁵, Lee-Suan Teh¹⁶, Mohammed Aki¹⁷, Neil J McHugh¹⁸,¹⁹, Asad Zoma²⁰ and Ian N. Bruce¹,² for the British Isles Lupus Assessment Group Biologics Register.

¹The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester, UK

²Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

³Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

⁴Reader in Vasculitis, Department of Medicine, University of Cambridge, Honorary Consultant Physician, Addenbooke's Hospital, Hills Road, Cambridge, UK

⁵Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, UK

⁶University College London, London, UK

⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

⁸Rheumatology department, City Hospital, Sandwell and west Birmingham Hospitals NHS Trust, Birmingham, UK

⁹Louise Coote Lupus Unit, Guys Hospital, London, UK

¹⁰Rheumatology Department- University Hospitals Birmingham NHS Foundation Trust, Old Queen Elizabeth Hospital, Birmingham, UK
Corresponding Author Professor Ian Bruce    Email ian.bruce@manchester.ac.uk

Postal Address Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK

Running Title Belimumab use in Refractory SLE

Key Words Systemic Lupus Erythematosus, Biologic Therapy, Rituximab, Belimumab, Register.
Belimumab, an anti B Lymphocyte Stimulator (BLYS) monoclonal antibody, has proven efficacy for the treatment of SLE [1, 2]. The European licence is based on post hoc analysis of randomised trials showing that predictors of better response include elevated antibodies to double-stranded DNA (dsDNA), low complement and higher SELENA-SLEDAI scores [3, 4]. Patients with severe active lupus nephritis or central nervous system lupus were excluded from these trials and do not form part of the patient population assessed as part of the marketing authorisation [1,2]. In June 2016 The National Institute for Clinical Excellence (NICE) recommended the use of belimumab as add-on therapy for patients with active auto-antibody positive SLE, who have serological activity (defined as positive anti-dsDNA and low complement) and a SELENA-SLEDAI score ≥10, despite standard treatment [5].

Since 2010 patients commencing biologic therapy for SLE in the UK have been registered in the British Isles Lupus Assessment Group Biologics Register (BILAG-BR), the initial results of which are presented elsewhere in this journal (ref).

We sought to investigate the number of patients and the clinical characteristics of patients treated with a biologic in the BILAG-BR who would potentially have been eligible for belimumab using this guidance [5].

Of the 270 patients registered for biologic use to Nov 2015, 82 (33%) had evidence of both low complement and elevated anti-dsDNA antibodies at enrolment. Of these, 46 (56.1%) patients had a BILAG A in the renal (n=29) or neuropsychiatric system (n=17) making them ineligible for therapy. An additional 4 (4.9%) had a SLEDAI score < 10. Thus from 2010-2015 32 patients (13%) enrolled in the BILAG-BR would have been eligible for belimumab.
Amongst these 32 patients the BILAG mucocutaneous (MUC) and musculoskeletal (MSK) systems had the most frequent A (MSK=7, MUC=6) and B scores (MSK=11, MUC=8) (Figure 1). 17 (53%) patients had a history of renal disease. The median (IQR) baseline SLEDAI was 12.5 (12 -15.75).

Regarding medication use 28 (87.5%) and 27 (84.4%) patients were on an anti-malarial or oral prednisolone respectively. The median (IQR) baseline prednisolone dose was 15mg (10mg-20mg). The median (IQR) number of prior standard immunosuppressant agents was 2 (1-3). Mycophenolate mofetil was the most frequently prescribed therapy (n=23) followed by azathioprine (n=15) and cyclophosphamide (n=11).

When we assessed response to RTX in this cohort who would now be eligible for belimumab, the median (IQR) SLEDAI improved from 12.5 (12-15.75) at baseline to 4 (0-8) at 6 months (p < 0.0001). The total number of BILAG A scores reduced from 16 to 2 and B scores from 33 to 9. A corresponding reduction in corticosteroid dose was also noted from 15mg (10mg-20mg) to 6mg (5mg-10mg) at 6 months (p < 0.001).

Improved access to biologic therapies will enhance physician’s ability to control disease activity whilst facilitating corticosteroid tapering and preventing damage [6]. Given the response rate to most biologic therapies in SLE is approximately 50%, the addition of belimumab to UK physicians’ armamentarium is to be welcomed, especially for those patients who have not responded to conventional therapy. Our data will help inform clinicians and planners about the expected rates of usage and the clinical characteristics of patients requiring belimumab in the UK. Mucocutaneous and musculoskeletal were the systems most likely to have active disease requiring belimumab. A history of renal involvement was however noted in approximately 50% of cases, emphasising that previous
renal involvement does not exclude patients from belimumab, indeed both the BLISS-52 and 76 trials included patients with active renal disease and a post hoc analysis suggested favourable renal outcomes in this population [7]. Our data also suggests that RTX remains a realistic therapeutic option for patients who fail to respond to belimumab.

In summary, between 2010 and 2015 13% of patients who commenced biologic therapy for SLE in the UK would have been eligible for belimumab. Access to such treatment offers the potential of improved disease control, corticosteroid dose reduction and improved long term outcomes for these patients.

Key messages

13% of UK SLE patients with disease requiring biologic therapy are eligible for belimumab.
Acknowledgements:

BILAG-BR collaborators – to be indexed by The National Library of Medicine (NLM)

Patrick Gordon: Department of Rheumatology, King's College Hospital, London, UK

Steven Young-Min: Portsmouth Hospitals NHS trust, Portsmouth, UK

Robert Stevens: Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, UK

Athiveer Prabu: Worcestershire Acute Hospitals NHS Trust and Sandwell and West Birmingham Hospitals NHS Trust.

Mike Batley: Maidstone and Tunbridge Wells NHS Trust, UK

Nagu Gendi: Basildon & Thurrock University Hospitals NHS Trust, Basildon, UK

Bhaskar Dasgupta: Southend University Hospital, Westcliff-on-sea, Essex, UK

Munther Khamashta: St Thomas’ Hospital, London, UK

Peter Hewins: Queen Elizabeth Hospital, Birmingham, UK

Richard J. Stratton: Royal Free Hospital, London, UK

Antoni Chan: Royal Berkshire Hospital, Reading, UK

Denise De Lord: Queen Elizabeth Queen Mary Hospital, East Kent, UK

Jon King: Derriford Hospital, Plymouth, UK

Shirish Dubey: University Hospital of Coventry and Warwickshire, UK

Edmond O'Riordan: Salford Royal Foundation Trust, Manchester, UK

Shireen Shaffu: Leicester Royal Infirmary, Leicester, UK

Cathy Laversuch: Musgrove Park Hospital, Taunton, Somerset, UK

TP Sheeran: Cannock Chase hospital

Erin Vermaak: Haywood Hospital

Nicola Erb: Dudley Group of Hospitals NHS FT, West Midlands, UK

Debasish Pyne: Barts Lupus Centre, Royal London Hospital, London, UK

Rachel Jeffrey: Northampton General Hospital, Northampton, UK

Hazem Youssef: Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, UK

Wahab Al-Allaf: New Cross Hospital, Wolverhampton, UK and University of Birmingham, Birmingham, UK

Marian Regan: Royal Derby Hospital, Derby, UK
**Arvind Kaul:** St. George’s University of London, Cranmer Terrace, London, UK

Dr Parker is supported by the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Prof Bruce is an NIHR Senior Investigator and is funded by Arthritis Research UK, the Medical Research Council, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

The Birmingham lupus cohort has been supported by Lupus UK, Sandwell and West Birmingham Hospitals NHS Trust and the NIHR/Wellcome Trust Birmingham Clinical Research Facility.

Prof Edwards is supported by the Southampton NIHR Biomedical Research Centre and Southampton NIHR Wellcome Trust Clinical Research Facility.

Dr. Arvind Kaul has received funding support for the BILAG-BR from The National Institute for Health Research Clinical Research Network (NIHR CRN) South London

Dr. Lee-Suan Teh would like to acknowledge Janice Hartley, Research and Development Department, Royal Blackburn Hospital, Blackburn, UK for help with data entry.

**Conflict of Interest Statement**
The authors declare no conflicts of interest.

**Funding Statement**

The register is funded by restricted income from UK pharmaceutical companies, presently Roche and GSK, through a contract with the University of Manchester. The principal investigators and their team have full academic freedom and are able to work independently of pharmaceutical industry influence. All decisions regarding analyses, interpretation and publication are made autonomously of any industry contribution. The registry has also received funding support from Lupus UK, a registered charity.
References


Figure 1. BILAG-2004 organ systems with active disease in SLE patients eligible for belimumab. (A) Number of individual patients scoring either an A or B on BILAG-2004 scoring system across the systems assessed.